1. Pink Sheet
  2. >>Geography
  3. >>Europe

Pharma Industry Advised To Prepare For Incoming EU AI Regulation

 
• By Eliza Slawther

The artificial intelligence revolution has arrived, but are pharmaceutical companies ready to meet the expectations of regulators? Lawyer Vincenzo Salvatore outlines the EU regulatory and policy developments that are relevant to the use of AI in the medicinal product lifecycle.

Artificial intelligence
• Source: Shutterstock

Artificial intelligence (AI) has the potential to streamline pharmaceutical R&D processes in a multitude of ways, from generating novel vaccine antibody designs to rapidly analyzing large swathes of clinical trial data.

However, with great potential comes great risk, at least in the eyes of the European Commission, which in April 2021 proposed the EU AI Act, which would

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 
• By Eliza Slawther

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.